No Abstract BioWorld International CorrespondentLONDON - Biocompatibles International plc moved onto the next stage of its collaboration with AstraZeneca plc, agreeing to a schedule for the Phase I and Phase II trials of the Type II diabetes drug CM3, and thus triggering a further €4.3 million (US$6.4 million) payment from the pharma company.